T-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis
Most studies on vaccines of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused on antibody, but cellular immunities are also critical. We aimed to evaluate the immune reactions of hemodialysis (HD) patients after the administration of the booster dose from the perspective of both humoral and cellular immunities. Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (control group) receiving three doses of BNT162b2 vaccine were measured for anti-SARS-CoV-2 immunoglobulin (IgG) and T-SPOTⓇ.COVID test (T-SPOT) before, 3 weeks, and 3 months after the booster dose. The HD group had significantly higher SARS-CoV-2 IgG levels 3 weeks and 3 months after the booster dose than the control group, although both groups had no difference in SARS-CoV-2 IgG levels before the booster dose. Moreover, the HD group had significantly higher T-SPOT levels before and 3 weeks after the booster dose than the control group, but the difference was not significantly different 3 months after the booster dose. Furthermore, the incidence rates of local and systemic adverse reactions were significantly higher in the HD group than in the control group. HD patients obtained higher SARS-CoV-2 IgG levels and SARS-COV-2-specific T-cell responses after the booster dose than control..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Preprints.org - (2022) vom: 07. Sept. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshifuji, Ayumi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.20944/preprints202209.0101.v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
preprintsorg037222910 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | preprintsorg037222910 | ||
| 003 | DE-627 | ||
| 005 | 20230429203905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20944/preprints202209.0101.v1 |2 doi | |
| 035 | |a (DE-627)preprintsorg037222910 | ||
| 035 | |a (preprintsorg)10.20944/preprints202209.0101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshifuji, Ayumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a T-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Most studies on vaccines of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have focused on antibody, but cellular immunities are also critical. We aimed to evaluate the immune reactions of hemodialysis (HD) patients after the administration of the booster dose from the perspective of both humoral and cellular immunities. Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (control group) receiving three doses of BNT162b2 vaccine were measured for anti-SARS-CoV-2 immunoglobulin (IgG) and T-SPOTⓇ.COVID test (T-SPOT) before, 3 weeks, and 3 months after the booster dose. The HD group had significantly higher SARS-CoV-2 IgG levels 3 weeks and 3 months after the booster dose than the control group, although both groups had no difference in SARS-CoV-2 IgG levels before the booster dose. Moreover, the HD group had significantly higher T-SPOT levels before and 3 weeks after the booster dose than the control group, but the difference was not significantly different 3 months after the booster dose. Furthermore, the incidence rates of local and systemic adverse reactions were significantly higher in the HD group than in the control group. HD patients obtained higher SARS-CoV-2 IgG levels and SARS-COV-2-specific T-cell responses after the booster dose than control. | ||
| 650 | 4 | |a Medicine & Pharmacology | |
| 650 | 4 | |a 610 | |
| 700 | 1 | |a Toda, Masataro |e verfasserin |4 aut | |
| 700 | 1 | |a Ryuzaki, Munekazu |e verfasserin |4 aut | |
| 700 | 1 | |a Oyama, Emi |e verfasserin |4 aut | |
| 700 | 1 | |a Kikuchi, Kan |e verfasserin |4 aut | |
| 700 | 1 | |a Kawai, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Koinuma, Masayoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Katayama, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Uehara, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohmagari, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Kanno, Yoshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kon, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Shinoda, Toshio |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Yaoko |e verfasserin |4 aut | |
| 700 | 1 | |a Hora, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakazawa, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Hanafusa, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Hinoshita, Fumihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Morikane, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Wakino, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamoto, Hidetomo |e verfasserin |4 aut | |
| 700 | 1 | |a Takemoto, Yoshiaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2022) vom: 07. Sept. |
| 773 | 1 | 8 | |g year:2022 |g day:07 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202209.0101.v1 |z kostenfrei |3 Volltext |
| 912 | |a preprintsorg | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 07 |c 09 | ||